医学新闻:Alzheimer's: molecular mechanism could lead to treatment

Marie Ellis2015/12/02英语学习

摘要: 阿尔茨海默病早期阶段存在一种由β-淀粉样蛋白介导的分子机制,可导致神经细胞黏附分子2(NCAM2)降解,进而引发突触丢失,这一过程发生在神经元死亡和明显认知症状出现之前。

  • 阿尔茨海默病早期即出现突触丢失,早于神经元死亡和临床症状明显化。
  • 研究发现神经细胞黏附分子2(NCAM2)在患者海马体中的水平显著降低。
  • β-淀粉样蛋白可直接降解NCAM2,破坏突触连接,影响学习与记忆功能。
  • 该机制为阿尔茨海默病的早期诊断和靶向治疗提供了新方向。
  • 随着患病人数预计到2050年增至1400万,开发基于此通路的疗法具有紧迫性。

小白老师说:因为公众号后台编辑器对标题的字数有限制,所以不得不把原文标题缩短,原标题附在文中。另外,小白老师挤时间为大家写了文章的英文摘要和Background Information,希望能为大家有效导读。

Abstract

During the early stages of Alzheimer’s disease, when individuals appear to be free of symptoms, toxic changes are nevertheless taking place in the brain - including synapse loss. Though scientists do not yet fully know what causes this form of dementia, researchers have found how brain cell connections are destroyed in early stages of the disease.

Fast facts about Alzheimer’s disease( Background information)

-— In 2013, 5 million Americans were living with Alzheimer’s

-— Age is the best-known risk factor for the condition; symptoms typically first appear after age 60

-— The risk increases with age

Alzheimer’s: newly identified molecular mechanism could lead to treatment

The researchers, led by scientists at the University of New South Wales (UNSW) in Australia, say their findings could lead to more research into possible treatments.

They publish their work the journal Nature Communications.

Alzheimer’s disease was first discovered by Dr. Alois Alzheimer in 1906, after he observed changes in the brain tissue of a woman who died of an odd mental illness, symptoms of which included memory loss and unpredictable behavior.

Upon examining her brain after death, Dr. Alzheimer found abnormal clumps - now known as amyloid plaques - and tangled fibers - now called tau tangles.

The leader of this latest study, Dr. Vladimir Sytnyk, from the UNSW School of Biotechnology and Biomolecular Sciences, explains that loss of synapses - which connect brain neurons - is one of the first changes associated with Alzheimer’s disease.

“Synapses are required for all brain functions,” he says, “and particularly for learning and forming memories.”

He adds that synapse loss occurs very early in Alzheimer’s disease, long before the nerve cells die, when only mild cognitive impairment is noticeable.

Low NCAM2 levels found in brains affected by Alzheimer’s

To further investigate brain changes related to Alzheimer’s disease, Dr. Sytnyk and colleagues looked at a brain protein called neural cell adhesion molecule 2 (NCAM2), which is part of a family of molecules that connects synapse membranes, helping maintain synaptic connections between neurons.

By studying brain tissue from people with and without the condition who had died, the team found that synaptic levels of NCAM2 in the hippocampus were low in the individuals with the disease.

In Alzheimer’s, most of the damage appears to take place in the hippocampus, which is the part of the brain that is essential in forming memories.

Additionally, through mice studies, the researchers found that NCAM2 was broken down by beta-amyloid proteins, which are the abnormal clumps that build up in the brains of people with Alzheimer’s.

“We have identified a new molecular mechanism, which directly contributes to this synapse loss,” says Dr. Sytnyk, “a discovery we hope could eventually lead to earlier diagnosis of the disease and new treatments.”

He adds:

“Our research shows the loss of synapses is linked to the loss of NCAM2 as a result of the toxic effects of beta-amyloid. It opens up a new avenue for research on possible treatments that can prevent the destruction of NCAM2 in the brain.”

Given that the number of people with Alzheimer’s disease is projected to increase three-fold by 2050, bringing the total to 14 million Americans, finding treatments for the condition is immensely important.

常见问题

NCAM2在阿尔茨海默病中起什么作用?

NCAM2是一种维持神经元突触连接的关键蛋白,在阿尔茨海默病患者海马体中水平显著降低,其降解由β-淀粉样蛋白引起,直接导致突触丢失。

为什么突触丢失对阿尔茨海默病很重要?

突触是大脑所有功能(尤其是学习和记忆)的基础,其丢失是阿尔茨海默病最早期的病理变化之一,早于神经元死亡和明显认知障碍。

这项研究如何推动新疗法开发?

研究揭示了β-淀粉样蛋白通过降解NCAM2破坏突触的新机制,为开发保护NCAM2或阻断该通路的治疗策略提供了潜在靶点。

参考资料

Alzheimer's: newly identified molecular mechanism could lead to treatment

原始新闻报道,提及研究发表于Nature Communications,由澳大利亚新南威尔士大学Vladimir Sytnyk团队完成。

Nature Communications - NCAM2 degradation links amyloid-β to synapse loss in Alzheimer’s disease

研究论文发表期刊,具体文章标题未提供,但内容描述与NCAM2和β-淀粉样蛋白机制一致。